Spasmomen

Quick links to important sections

Spasmomen

Method of action: Antispasmodic

Treatment option: Gastritis, Colitis, Esophagitis, Enteritis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spasmomen

Property Description
Active ingredient Otilonium Bromide
Form Typically an Oral Tablet/Film-Coated Tablet
Pharmacological class Antispasmodic / Calcium Channel Blocker
Common use Relief of gastrointestinal spasms and cramping
Origin Synthetic Chemical

This medicine, marketed under the brand name Spasmomen, is a type of antispasmodic agent specifically designed to relieve painful muscle contractions in the digestive tract. The active ingredient, otilonium bromide, is a synthetic compound that belongs to the spasmolytic class of medications primarily targeting the smooth muscles of the gut. Spasmomen is typically supplied as film-coated tablets for oral administration.

General Therapeutic Purpose

Spasmomen is primarily used to manage symptoms associated with functional bowel conditions, such as Irritable Bowel Syndrome (IBS). Its function is to provide targeted relief from the chronic pain and discomfort caused by involuntary spasms (cramping) within the intestinal wall.

Supporting Facts and Uniqueness

Otilonium bromide is classified pharmacologically as a Calcium Channel Blocker, a mechanism that is clinically recognized for its ability to help regulate muscle contractions in the intestines. This means the medicine works by blocking signals that tell the gut muscles to tighten painfully.

A key differentiating feature of the active ingredient is its design for localized action. With low systemic absorption, the therapeutic benefits are concentrated directly on the intestinal wall, thus minimizing potential impact on other body systems. This targeted approach is intended to provide focused relief from gut spasms without causing widespread effects.

Regulatory References

  1. National Institutes of Health - PubMed

What side effects are possible with Spasmomen?

Official Adverse Reactions and Safety Classification

The safety profile of otilonium bromide (Spasmomen) is officially documented with a low frequency of adverse reactions, consistent with its design for localized action on the gastrointestinal tract and low systemic absorption. The frequency of documented effects is generally classified as uncommon (affecting up to 1 in 100 people) or not known (cannot be estimated from the available data), based on regulatory standards.

System-Organ Classes and Documented Effects

Adverse reactions are grouped by the body systems affected, as per official regulatory classification:

System-Organ Class Documented Effects
Gastrointestinal disorders Nausea, Upper abdominal pain, Dry mouth
Skin and subcutaneous tissue disorders Pruritus (itching), Erythema, Skin hypersensitivity (e.g., Angioedema)
Nervous system disorders Headache, Dizziness (Vertigo)
General disorders Fatigue, Asthenia (lack of energy)

Safety Restrictions and Constraints

The official safety information outlines specific contraindications—situations where the medicine should not be used—due to the potential for its anticholinergic-like properties to exacerbate certain pre-existing conditions. These regulatory constraints include individuals with glaucoma, prostatic hypertrophy, and pyloric stenosis.

Additionally, the medicine is generally not recommended for individuals under 18 years of age as the safety and efficacy data for this population are not definitively established in regulatory documents.

Overdose and Emergency Response

The official regulatory documentation for otilonium bromide (Spasmomen) addresses overdose based on the drug's pharmacological profile, which is associated with negligible systemic absorption. Due to this characteristic, adverse effects are not expected if the maximum recommended dose is exceeded. Regulatory assessments and available clinical data indicate that no specific, severe manifestations or life-threatening outcomes are typically documented as a direct result of overdose in humans.

Despite the low expected toxicity, immediate action is required upon consuming more than the prescribed amount. Regulatory guidance mandates that individuals must seek medical advice immediately following an overdose, even if they currently feel well. It is specifically stated that a patient must contact a doctor or the emergency department if they notice that they are not feeling well or experience any unexpected change in their condition.

In the event of an overdose, the treatment approach described in the official documents is limited to symptomatic and supportive treatment. No specific antidote for otilonium bromide is documented in the authorized prescribing information. Management procedures focus entirely on addressing any symptoms that may arise and maintaining functional stability until the compound is cleared from the system.

Therapeutic Uses of Spasmomen

What Spasmomen Treats: Main Uses and Benefits

Spasmomen (otilonium bromide) is commonly used to help manage symptoms related to functional stress and discomfort. The core therapeutic domain of this medication involves managing symptoms related to physical discomfort and conditions presenting with systemic or localized discomfort, such as Irritable Bowel Syndrome (IBS).

The medicine is applied across domains where additional symptomatic support is needed, and its therapeutic scope is defined within its clinical indications.


Easing Noticeable Digestive Discomfort

This medicine is used in situations involving certain distressing symptoms, helping to address symptom clusters that may become intense or disruptive. It is relevant when groups of symptoms, such as abdominal discomfort, appear suddenly or fluctuate. It provides support that helps ease the overall burden of symptoms. It also contributes to improved comfort during periods of heightened symptoms.

Supportive Management for Episodic Symptoms

Spasmomen is relevant in conditions characterized by periods of heightened symptoms, particularly those involving recurrent or episodic manifestations. It is commonly used when symptoms intensify and supportive relief is needed. It supports patients during difficult episodes by easing distress and may also assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Used for managing symptoms related to systemic or localized discomfort


Addressing Symptoms That Interfere with Daily Stability

This therapeutic agent is applied when symptoms create noticeable functional strain or interfere with daily functioning, often in contexts marked by increased systemic burden. It provides supportive relief when symptoms become temporarily overwhelming. It can help maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. Ethiopian Food and Drug Authority

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Spasmomen

Official regulatory documents define the allowed and restricted populations for Spasmomen (otilonium bromide) based on age, physiological status, and pre-existing conditions.

Eligibility scope
Populations for whom use is allowed (as stated in label): Adults (patients older than 18 years). Dose adjustment is not necessary for older adults.
Populations for whom use is not recommended: Pediatric population (under 18 years), Pregnant women, and Nursing mothers (unless absolutely necessary and under close medical supervision).
Populations for whom use is contraindicated: Individuals with known hypersensitivity to otilonium bromide or any excipients; patients with rare hereditary problems like galactose intolerance or lactase deficiency due to the presence of lactose.

Eligibility classifications (high-level)
Condition-specific eligibility rules: Use requires caution in patients with glaucoma, prostatic hypertrophy (enlarged prostate), and pyloric stenosis (narrowing of the stomach outlet).
Use-not-established groups: Safety and efficacy have not been established in children and adolescents under 18. Use in patients with impaired renal and hepatic function has not been specifically studied.

Connection to the overall eligibility profile:

The eligibility profile strictly limits Spasmomen's use to the adult population (18+), based on the lack of established safety data in children. Absolute prohibition is defined by hypersensitivity and certain metabolic disorders. The label mandates caution for specific co-morbidities like glaucoma and prostatic hypertrophy, and classifies use during pregnancy and lactation as not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Spasmomen (otilonium bromide) is characterized by a minimal potential for interaction with other medicinal products. This classification is primarily based on the drug's pharmacokinetic properties, specifically its design for localized action within the gastrointestinal tract and its minimal systemic absorption.

Official documentation frequently reports that no formal interaction studies were performed because the low systemic exposure of otilonium bromide suggests a negligible risk of affecting the systemic clearance or metabolism of co-administered medicines. The drug's effect on the overall intestinal transit time is considered not relevant to the absorption of other orally administered products.

Interaction Type Regulatory Status
Drug–Drug Interactions None documented.
Metabolic (CYP) Interactions None documented.
Timing Restrictions None required.
Contraindicated Combinations None documented based on interaction risk.

The regulatory section for interactions with other medicaments is often formally listed as "None" in the Summary of Product Characteristics (SmPC).

Regarding interactions with non-medicinal substances, official patient information confirms that there are no known interactions between Spasmomen and food or drink. No specific interaction is documented for alcohol or herbal products. The overall interaction structure reflects a product whose therapeutic focus is confined to the gut, thereby limiting systemic interaction potential.

Mechanism of Action

Spasmomen, which contains otilonium bromide, exerts its action through a multifaceted pharmacodynamic mechanism concentrated on the smooth muscle of the distal gastrointestinal (GI) tract. The compound alters pathway activity associated with hypercontractility, influencing the overall physiological state of the intestinal system.

Calcium Channel Blockade in GI Smooth Muscle

The primary interaction involves the inhibition of L-type and T-type calcium channels on the smooth muscle cell membrane. By limiting the influx of extracellular calcium ions ( Ca^2+), which are essential co-factors for initiating smooth muscle contraction, the reduction in Ca^2+ availability decreases the activation and intensity of contractile force generation.

Receptor-Mediated Signaling Modulation

Additionally, otilonium bromide interferes with receptor-mediated signaling cascades contributing to enhanced GI motility. Specifically, it functions as an antagonist at muscarinic receptors and exhibits activity at tachykinin NK2 receptors. This receptor modulation dampens signaling sequences that promote increased GI tract hypercontractility, contributing to the resulting physiological adjustment of decreased muscle contractility.

Dosage and Administration Information

Instruction Map: How to use Spasmomen — Administration Guidelines

This section outlines the protocol for administering otilonium bromide (Spasmomen). These guidelines define the route, dosage, frequency, and conditions for intake.


Administration Scope

Feature Detail
Route of administration The medicine is designed for oral administration.
Dosing schedule The standard regimen for adults and the elderly is a 40 mg tablet taken two to three times daily. This establishes a total daily dose ranging from 80 mg to 120 mg.
Timing in relation to meals (if applicable) The tablet should be taken preferably 20 minutes before a meal with a glass of water.
Age-group administration rules The standard dosing applies to adults and elderly patients. The medication is not recommended for use in patients below 18 years as safety and efficacy have not been established in this population.
Missed-dose rules If a dose is forgotten, it should be taken as soon as it is remembered. However, a double dose must not be taken to compensate for the forgotten tablet.

Instruction Classifications (high-level)

Feature Classification
Administration method type Oral
Frequency pattern Divided daily use
Use-context constraints Pre-meal timing and whole tablet intake

Resulting procedural structure

Standard step sequence:

  • The tablet is administered orally in a 40 mg dose.
  • The tablet must be taken 2 to 3 times daily, with a maximum daily intake of 120 mg.
  • The tablet must be swallowed whole with water and must not be crushed or chewed.
  • Treatment duration has no fixed limitation and is determined by the course of the patient's condition.

Connection to the overall use protocol: The instructions establish an oral administration schedule to ensure consistent intake within a recommended dose range of 80 mg to 120 mg daily. The required pre-meal timing and the explicit rule to swallow the tablet whole dictate the essential physical procedure for administering the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spasmomen

Evidence for Use in Irritable Bowel Syndrome (IBS) and Spasm

The research base for otilonium bromide (Spasmomen) primarily consists of multiple large-scale Randomized Controlled Trials (RCTs), a study type used to rigorously explore changes in specific, measured outcomes. These studies were applied in research contexts involving functional bowel conditions and were designed to explore how symptoms change over defined time intervals, typically comparing the medicine against a placebo. Further understanding is derived from meta-analyses and pooled reports, which combine the data from many separate trials.

Research examined outcomes related to physical discomfort and functional imbalance in the digestive tract, as captured by patient reports. Studies monitored patient-reported outcomes for changes in the frequency and intensity of abdominal pain and cramping. Research also explored outcomes related to episodes of discomfort, such as the severity of abdominal bloating and distension.

  • How Core Efficacy Outcomes Were Measured in Trials

Crucial measures used by researchers involved patient-reported outcomes describing perceived discomfort. These included the Global Assessment of Relief, which monitored the overall change in symptoms as reported from the patient's perspective, and standardized scales for measuring changes in symptom intensity.

Long-Term Evidence and Durability of Study Observations

The main efficacy trials for Spasmomen typically evaluated the medicine over short-term to intermediate treatment periods, commonly ranging from 4 to 15 weeks. These follow-up durations were limited in the initial registration studies. Some trials included a subsequent post-treatment observation period to explore patterns related to symptom stability and the timing and rate of symptom return (relapse). Long-term effects are not fully established, and there is limited information for outcomes extending beyond one year.

What Remains Uncertain in the Research Landscape

Findings were mixed or showed inconsistency across studies for certain secondary outcomes, particularly all measures related to the normalization of stool frequency and consistency. Research provides insight into short-term changes, but there is still some uncertainty regarding the consistency of observations across all related bowel functions.

Key Studies & References

  1. Otilonium bromide 40 mg film coated tablets - Spasmomen - Summary of Product Characteristics (Ethiopian Food and Drug Authority)

Frequently Asked Questions (FAQ)

Common questions about Spasmomen (FAQ)


Q: How long does it usually take for Spasmomen to start working?

Official information notes that the exact time required to show its action is not clinically established. However, consistent with its design for localized action on the gastrointestinal tract and minimal systemic absorption, its intended action to reduce motility and cramping is suggested to begin relatively soon after oral intake.


Q: How long does the effect of one tablet of Spasmomen last?

The precise duration of action for a single tablet is not formally stated in official product documents. The standard regimen for this medicine is typically structured for continuous daily use, generally involving intake two to three times daily to maintain the therapeutic effect throughout the day.


Q: Can Spasmomen be taken with blood pressure medication?

Regulatory documents report no documented drug-drug interactions because the medicine has minimal systemic absorption. However, its side effect profile includes reports of hypotension (low blood pressure) and palpitations; therefore, prescribers typically exercise caution when it is co-administered with blood pressure medication (antihypertensives).


Q: Does Spasmomen affect the kidneys or liver?

Official information states that the medicine is not specifically studied in patients with impaired kidney or liver function. Nevertheless, due to its minimal systemic absorption, the drug is primarily designed to act locally, and an effect on these organs is not indicated.


Q: Can Spasmomen be used for painful periods (menstrual cramps)?

According to the official product information, the approved purpose is confined to the treatment of symptoms of Irritable Bowel Syndrome (IBS) and other functional disorders of the lower gastrointestinal (GI) tract. The medicine is not indicated for the treatment of menstrual cramps (dysmenorrhea).


Q: Is Spasmomen only for adults?

Yes, the standard dosing applies to adults and the elderly. Official documents state that the medicine is not recommended for use in children under 18 years of age because safety and effectiveness in this younger population have not been established.


Q: Is Spasmomen the same as other stomach cramp medicines?

Spasmomen contains the active ingredient otilonium bromide, which is one type of antispasmodic. It is distinguished by its dual mechanism of action (functioning as a Calcium Channel Blocker and receptor antagonist) and its design for highly localized action on the gut with minimal systemic absorption.


Q: Is Spasmomen considered a strong medicine?

Spasmomen is classified as a prescription-only antispasmodic used to treat the specific, often chronic, symptoms of conditions like IBS. Its 'strength' is often characterized by its targeted, selective action on the smooth muscle of the gastrointestinal tract, which has been shown in studies to significantly reduce abdominal pain and bloating.


Q: Do you have to take Spasmomen every day?

The official dosing schedule requires divided daily use (two to three times daily). The therapeutic effect observed in clinical trials, which established the drug's effectiveness, was achieved over a sustained period of continuous daily dosing.


Q: Is there a generic version of Spasmomen?

Spasmomen is a brand name for the active ingredient otilonium bromide. The drug is available under its chemical name, otilonium bromide, which acts as its generic equivalent.


Q: What does 'spasmolytic' mean in simple terms?

The term 'spasmolytic' or 'antispasmodic' refers to a medicine that works to relieve or prevent spasms. These spasms are the painful, involuntary contractions of the smooth muscle found in organs such as the intestines.


Q: Is Spasmomen safe for people with gluten or lactose intolerance?

The official documentation lists certain hereditary problems related to lactose as a contraindication because the tablet contains lactose. However, official documents do not provide specific information regarding gluten content.


Q: What should I do if the medicine doesn't seem to be working?

If the medicine does not appear to be working, the required procedural step is to consult the prescribing healthcare professional. They are best positioned to review the ongoing need for the medicine and determine the next steps in the management plan.


Q: Has there been new research published on Spasmomen recently?

The evidence base for otilonium bromide continues to be updated with new data. This includes recently published Randomized Controlled Trials (RCTs) and ongoing studies that explore the use of the drug in combination therapies or provide extended analyses of existing trial data.


Q: Is Spasmomen known by a different name internationally?

Yes, the active ingredient otilonium bromide is marketed under several regional brand names worldwide, such as Spasmoctyl or MenocTYL, in addition to Spasmomen.


Q: Does Spasmomen cause weight changes?

The official list of documented adverse reactions (side effects) found in regulatory summaries does not include weight change (gain or loss). This observation is not typically reported as a frequent adverse event in clinical trials.


Q: Is it safe to drink coffee while taking Spasmomen?

Official documents state that there are no known interactions between Spasmomen and food or drink. Given the drug's minimal systemic absorption, the risk of a metabolic interaction with compounds like caffeine is considered low.


Q: Is Spasmomen prescribed for headaches?

No, Spasmomen is prescribed only for gastrointestinal functional disorders associated with spasms. Headache is listed in the official documents as an uncommon documented adverse reaction (side effect) of the medicine, not an approved reason for its use.


Q: What happens if I stop taking Spasmomen suddenly?

There is no regulatory documentation of a specific withdrawal syndrome following abrupt cessation. Clinical studies have shown that the therapeutic effects may persist for some time after the medicine is discontinued, which suggests a reduced rate of symptom relapse compared to placebo.


Q: Is it okay to take Spasmomen for sudden, sharp stomach pain?

The medicine is indicated for the treatment of symptoms associated with chronic functional bowel disorders. The official dosing schedule is a divided daily regimen for sustained relief, and not typically designed for single, as-needed use for acute or sudden pain.


Q: What is the difference between Spasmomen and Buscopan (or similar antispasmodic)?

Spasmomen is distinguished by its minimal systemic absorption and its dual mechanism of action (blocking both calcium channels and receptors). This design aims to focus the therapeutic effect directly on the smooth muscle of the gut while limiting systemic exposure.


Q: How reliable is the evidence supporting Spasmomen's use?

The evidence base is substantial, primarily consisting of Randomized Controlled Trials (RCTs) that have demonstrated superiority over placebo in reducing the frequency of abdominal pain and bloating. However, some studies reported mixed or inconsistent results for secondary outcomes like stool consistency.


Q: Does Spasmomen affect contraception (birth control pills)?

Official regulatory documents indicate that there are no documented drug-drug interactions listed for Spasmomen. Due to its minimal systemic absorption, the medicine is not expected to affect the systemic clearance or metabolism of co-administered medicines, including oral contraception.


Q: Can this drug be used by people with a history of heart problems?

The medicine's active ingredient is classified as a Calcium Channel Blocker, which is a drug class that can affect the cardiovascular system. Official documents list cardiovascular events (like palpitations) as rare adverse effects. For this reason, caution is typically exercised by prescribers.

How should Spasmomen be stored and disposed of?

How to Store and Dispose of Spasmomen

The storage and disposal of Spasmomen (otilonium bromide) must strictly adhere to the conditions outlined in official regulatory documents to ensure stability and environmental safety.

Official Storage Conditions

Requirement Constraint
Temperature Store below 30 C (86 F).
Protection Keep the medicine out of the sight and reach of children.
Stability Do not use the tablets after the expiry date printed on the packaging.

Disposal Requirements

Official instructions prohibit discarding unused or expired tablets into wastewater (sinks or toilets) or with household waste. These measures are necessary to protect the environment. Users are instructed to ask a pharmacist for the correct method to dispose of medicines they no longer need.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spasmomen found in:

A-Z Index: